S. Michael Imperiale
Corporate Officer/Principal chez PARADIGM BIOPHARMACEUTICALS LIMITED
Profil
S.
Michael Imperiale is currently the Chief Safety Officer at Paradigm Biopharmaceuticals Ltd.
He previously worked as the Senior Director-Medical Sciences at Nuvelo, Inc. from 2004 to 2007.
He also held positions as the Senior Director-Global Medical Affairs at BioMarin Pharmaceutical, Inc., Director-Clinical Science at InterMune, Inc., Director-Clinical Trials Development at Exelixis, Inc., and Independent Director at ScripsAmerica, Inc. Additionally, he served as the Senior Associate Director-Clinical Scientific at Boehringer Ingelheim Pharmaceuticals, Inc. from 2000 to 2004.
From 2007 to 2009, he was the Vice President-Clinical Research Operations at Talon Therapeutics, Inc. Dr. Imperiale obtained his undergraduate degree from Villanova University in 1982 and his doctorate degree from Hahnemann University in 1987.
Postes actifs de S. Michael Imperiale
| Sociétés | Poste | Début |
|---|---|---|
| PARADIGM BIOPHARMACEUTICALS LIMITED | Corporate Officer/Principal | 01/06/2020 |
Anciens postes connus de S. Michael Imperiale
| Sociétés | Poste | Fin |
|---|---|---|
Talon Therapeutics, Inc.
 Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Chief Tech/Sci/R&D Officer | 01/01/2009 |
| Nuvelo, Inc. | Chief Tech/Sci/R&D Officer | 01/01/2006 |
| EXELIXIS, INC. | Corporate Officer/Principal | 01/01/2006 |
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Corporate Officer/Principal | 01/01/2004 |
| INTERMUNE INC | Chief Tech/Sci/R&D Officer | - |
Formation de S. Michael Imperiale
| Villanova University | Undergraduate Degree |
| Hahnemann University | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| EXELIXIS, INC. | Health Technology |
| SCRIPSAMERICA, INC. | Distribution Services |
| PARADIGM BIOPHARMACEUTICALS LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
| Nuvelo, Inc. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Talon Therapeutics, Inc.
Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Health Technology |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
